文献速递淋巴瘤

伊布替尼联合维奈克拉对比单药在TCL1慢性淋巴细胞白血病小鼠模型中的研究

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该研究在模拟侵袭性慢性淋巴细胞白血病(CLL)的Eµ-TCL1过继转移小鼠模型中,比较了伊布替尼与维奈克拉联合治疗与单药持续治疗的疗效及机制。联合治疗产生最深缓解且持续时间最长,伴随增殖减少和凋亡增加;T细胞亚群改变在联合治疗后最显著,表现为初始T细胞增加和效应记忆T细胞减少。但单药及联合治疗最终均因复发而中断,BIM表达下调可能是获得性耐药的合理原因。

要点

  • 在Eµ-TCL1小鼠模型中,伊布替尼联合维奈克拉的疗效优于单药治疗。
  • 联合治疗诱导最深缓解,与增殖减少和凋亡增加相关。
  • 联合治疗可逆转CLL相关T细胞亚群异常,但最终仍出现复发。

核心结论

  • 在小鼠模型中,维奈克拉联合伊布替尼的疗效优于单药,并伴随T细胞区室的恢复。

研究设计与样本

  • 研究采用模拟侵袭性CLL的Eµ-TCL1过继转移小鼠模型,比较联合治疗与单药持续治疗。

主要发现

  • 联合治疗产生最深缓解,缓解持续时间最长,与增殖减少和凋亡诱导增加相关。
  • 联合治疗后T细胞亚群改变最显著,初始T细胞增加而效应记忆T细胞减少。
  • 单药及联合治疗最终均因复发而中断,BIM表达下调可能是获得性耐药的合理原因。

局限性

  • 研究基于小鼠模型,结果不能直接推及CLL患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The covalent inhibitor of Bruton's tyrosine kinase ibrutinib and the specific Bcl-2 inhibitor venetoclax are both highly efficacious single-agent drugs in the treatment of chronic lymphocytic leukemia (CLL). Based on their complementary modes of action, ibrutinib and venetoclax are hypothesized to act in a synergistic fashion. Currently, it is unclear whether combined treatment is indeed superior to continuous single-agent treatment and what mechanisms underlie the resistance to combination treatment. In addition, the effects of such treatment on the skewed T-cell compartment characteristic of CLL are as yet unknown. In the murine Eµ-TCL1 adoptive transfer model resembling aggressive CLL, we found that combined treatment resulted in the deepest responses, with the longest duration related to a combination of decreased proliferation and increased induction of apoptosis. In addition, alterations in T-cell subsets were most prominent after combination treatment, with increased naive cells and reduced effector memory cells. Remarkably, effects of single agents but also combination treatment were eventually interrupted by relapse, and we found downregulation of BIM expression as a plausible cause of acquired drug resistance. Nevertheless, in this murine model, the combination of venetoclax and ibrutinib has increased efficacy over single agents, accompanied by a restoration of the T-cell compartment.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Kater AP, Slinger E, Cretenet G, et al. Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv. 2021. PMID: 34555843. doi:10.1182/bloodadvances.2021004861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。